95,854 real consumer conversations reveal how GLP-1 medications are silently restructuring demand across grocery, apparel, beauty, and fitness before it shows up in your dashboards.
Consumer conversations analyzed
Opinions extracted
Jan 2022 to Dec 2025

With 1 in 8 U.S. adults on GLP-1 medications and oral formulations launching in 2026, consumer behavior is reorganizing in real time. The retailers who wait for point-of-sale confirmation are designing around yesterday's demand.
Each domain is not a separate trend. They are the same consumer reorganizing their spending around biological maintenance, capability preservation, and identity recovery. Miss one, and you miss the system.
This report includes role-specific strategy sections for the leaders most impacted by GLP-1 demand shifts.
10 chapters of behavioral intelligence translated into operational retail strategy, from forecast recalibration to adjacency capture.
Consumer routines around GLP-1 are still forming. Retail architectures around these behaviors have not yet been claimed at scale. Retailers who act on formation signals now will hold structural positions when revenue confirmation arrives. Those who wait will find them occupied.
Download the Full Report